Sickle Cell Disease Treatment Market By Type (Hemoglobin SS, Hemoglobin SC, Sickle Cell Beta Thalassemia, Sickle Hemoglobin-D Disease), By Treatment (Medication (Hydroxyurea, L-glutamine, Crizanlizumab, Others), Gene Therapy, Blood Transfusions, Bone Marrow Transplant), By End User (Hospitals, Specialty Clinics, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026-2035

Market Overview

Global Sickle Cell Disease Treatment Market size is expected to be worth around US$ 16.8 Billion by 2035 from US$ 3.5 Billion in 2025, growing at a CAGR of 17.0% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 42.1% share with a revenue of US$ 1.5 Billion.

Sickle Cell Disease (SCD) is an inherited blood disorder caused by mutations affecting hemoglobin, the protein responsible for carrying oxygen in red blood cells. The condition causes red blood cells to become rigid and sickle-shaped, which can restrict blood circulation and lead to complications such as severe pain episodes, anemia, stroke, and organ damage.

In the United States, SCD affects approximately 100,000 people, creating a continued need for advanced treatment solutions and improved disease management approaches. The Sickle Cell Disease Treatment Market is evolving with advancements in disease-modifying medicines, blood transfusion approaches, stem cell transplantation, and gene-based therapies.

According to the National Heart, Lung, and Blood Institute (NHLBI), currently available treatment options include hydroxyurea, L-glutamine, crizanlizumab, blood transfusions, hematopoietic stem cell transplantation, and gene therapy. Hydroxyurea remains a key therapy, with NHLBI-supported research demonstrating its ability to reduce pain crises in patients with severe SCD.

A major milestone in SCD treatment occurred in December 2023, when the U.S. Food and Drug Administration (FDA) approved two cell-based gene therapies, Casgevy and Lyfgenia, for patients aged 12 years and older with SCD. Casgevy became the first FDA-approved treatment using CRISPR/Cas9 genome-editing technology, representing a significant advancement toward addressing the underlying genetic cause of the disease.

Growing adoption of newborn screening programs is also supporting earlier diagnosis and treatment initiation. The CDC reports that newborn screening for SCD is conducted in every U.S. state, helping identify affected individuals and improving access to early medical care.

Increasing research investment, expansion of precision medicine, and development of next-generation genetic therapies are expected to strengthen the treatment landscape by improving long-term outcomes and expanding therapeutic options for individuals living with SCD.

Key Takeaways

• Market Size: Global Sickle Cell Disease Treatment Market size is expected to be worth around US$ 16.8 Billion by 2035 from US$ 3.5 Billion in 2025.
• Market Share: The market is growing at a CAGR of 17.0% during the forecast period from 2026 to 2035.
• Type: In 2025, Hemoglobin SS segments dominate the market with a 56.3% share.
• End User: In 2025, Hospitals segments dominate the market with a 67.5% share.
• Treatment: In 2025, Medication segments dominate the market with a 42.1% share.
• Distribution Channel: In 2025, Hospital Pharmacies segments dominate the market with a 52.7% share.
• Regional Analysis: In 2025, North America led the market, achieving over 42.1% share with a revenue of US$ 1.5 Billion.

Type Analysis

Hemoglobin SS segment dominates the Sickle Cell Disease Treatment Market.

The Type segment is primarily categorized based on the genetic variations and clinical manifestations of the disease, including Hemoglobin SS, Hemoglobin SC, Sickle Cell Beta Thalassemia, and Sickle Hemoglobin-D Disease.

In 2025, Hemoglobin SS segments dominate the market with a 56.3% share, driven by its higher prevalence and more severe disease progression compared with other sickle cell variants. Hemoglobin SS, also known as sickle cell anemia, is associated with frequent vaso-occlusive crises, chronic anemia, and increased demand for long-term disease management therapies.

Hemoglobin SC segments accounted for 28.2% of the market, supported by growing diagnosis rates and treatment requirements for patients experiencing moderate clinical complications. Sickle Cell Beta Thalassemia represented 9.7%, with demand increasing due to improved genetic screening and specialized treatment approaches.

Sickle Hemoglobin-D Disease contributed 5.8%, representing a smaller but clinically important segment requiring targeted management. Rising awareness, newborn screening programs, and advancements in disease-modifying therapies are supporting growth across all sickle cell disease types.

End User Analysis

Hospitals segment dominates the Sickle Cell Disease Treatment Market.

The End User segment Market includes Hospitals, Specialty Clinics, and Others. In 2025, Hospitals segments dominate the market with a 67.5% share, primarily due to their role as major treatment centers offering comprehensive sickle cell disease management services. Hospitals provide access to hematologists, advanced diagnostic facilities, emergency care, blood transfusion services, and advanced therapies such as gene-based treatments and bone marrow transplantation.

Specialty Clinics accounted for 19.2% of the market, supported by increasing demand for dedicated hematology care and personalized treatment plans. These clinics offer focused disease monitoring, pain management programs, and long-term follow-up services for patients with chronic sickle cell conditions. Others segments contributed 13.4%, including research institutions, ambulatory care centers, and specialized healthcare facilities involved in diagnosis and supportive treatment.

Increasing healthcare infrastructure, improved patient access, and the expansion of specialized sickle cell treatment programs are strengthening the role of hospitals and specialty clinics. The growing adoption of advanced therapies is also encouraging collaboration between hospitals and specialized care providers to improve patient outcomes.

Treatment Analysis

Medication segment dominates the Sickle Cell Disease Treatment Market.

The Treatment segment of the Sickle Cell Disease Treatment Market includes Medication, Gene Therapy, Blood Transfusions, and Bone Marrow Transplant. In 2025, Medication segments dominate the market with a 42.1% share, driven by widespread use of disease-modifying drugs such as Hydroxyurea, L-glutamine, Crizanlizumab, and other supportive therapies. These medications help reduce pain crises, manage complications, and improve quality of life among sickle cell patients.

Gene Therapy is the fastest-growing segment, supported by significant advancements in genetic medicine and the introduction of innovative therapies targeting the underlying genetic cause of sickle cell disease. Increasing investments in clinical research and regulatory approvals are accelerating adoption of gene-based treatment approaches.

Blood Transfusions remain an essential treatment option, particularly for patients with severe anemia, stroke prevention requirements, and acute complications. Bone Marrow Transplant represents a curative treatment approach for eligible patients, although adoption is limited due to donor availability, procedure complexity, and associated risks.

Growing innovation in precision medicine, improved treatment accessibility, and increasing focus on curative therapies are expected to reshape the treatment landscape of the sickle cell disease market.

Distribution Channel Analysis

Hospital Pharmacies segment dominates the Sickle Cell Disease Treatment Market.

The Distribution Channel segment includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. In 2025, Hospital Pharmacies segments dominate the market with a 52.7% share, owing to their direct association with specialized treatment centers and hospitals managing sickle cell patients. Hospital pharmacies ensure availability of prescription medications, infusion therapies, and specialized treatments while supporting physician-guided treatment protocols.

Retail Pharmacies represent a significant segment and are projected to be the fastest-growing distribution channel, driven by increasing accessibility, expanding community healthcare networks, and rising demand for long-term medication management outside hospital settings. Retail pharmacies provide convenient access to commonly prescribed sickle cell medications and supportive therapies.

Online Pharmacies are gaining momentum due to increasing digital healthcare adoption, improved prescription delivery services, and growing patient preference for convenient medication access. The expansion of e-pharmacy platforms and healthcare digitization is supporting their gradual adoption, especially among patients requiring regular medication refills.

Overall, improved healthcare accessibility, digital transformation, and increasing demand for continuous sickle cell disease management are strengthening growth across all distribution channels.

Key Market Segments

Type

• Hemoglobin SS
• Hemoglobin SC
• Sickle Cell Beta Thalassemia
• Sickle Hemoglobin-D Disease

Treatment

• Medication
  • Hydroxyurea
  • L-glutamine
  • Crizanlizumab
  • Others
• Gene Therapy
• Blood Transfusions
• Bone Marrow Transplant

End User

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Drivers

Gene therapy commercialization and referral center buildout.
FDA approval of Casgevy and Lyfgenia introduced the first commercial gene therapies for sickle cell disease, shifting the market from chronic symptom management to high value one time treatments for patients aged 12 years and older with recurrent vaso occlusive crises.

Each treated patient now represents multi million dollar revenue potential, with launch era prices around 2.2 million dollars for Casgevy and 3.1 million dollars for Lyfgenia, materially expanding the market value ceiling even with limited early throughput.

Adoption is constrained by transplant center capacity, conditioning requirements, long term follow up, and complex referral logistics, but these barriers are also driving investment in qualified treatment centers, cell handling infrastructure, and monitoring capabilities that expand the treatable base over time.

The impact is strongest in North America, where regulatory approval, reimbursement mechanisms, and specialist density are most aligned, while other regions are likely to adopt more gradually through selective reimbursement and center accreditation.

Challenges

Multi million dollar gene therapies slow broad market penetration globally.
Gene therapies expand the clinical impact and theoretical value of sickle cell disease treatment, but prices around 2.2 to 3.1 million dollars per course create a persistent cost overhang that slows adoption.

These prices far exceed chronic therapy economics and remain out of reach for most patients in low and middle income countries, where health spending is limited and out of pocket costs dominate.For payers, a single gene therapy can absorb budgets that would otherwise treat many patients with established regimens, leading to strict eligibility rules and staged rollout.

As a result, even if 5 to 10% of patients in high income countries are clinically eligible, uptake is likely to remain in the low single digits for years. This slows revenue realization and trims roughly 1.1 percentage points from potential global CAGR, making affordability and payment innovation a multi year constraint on market expansion.

Restraints

Low screening, diagnosis and adherence rates restricting demand.
The SCD treatment market is constrained by underdiagnosis, delayed diagnosis, and suboptimal adherence in high-burden regions, structurally limiting demand for both current and future therapies. Although an estimated 7.74 million people were living with SCD globally in 2021 and 515,000 babies were born with the disease roughly four-fifths in sub-Saharan Africa.

Many patients lack access to neonatal screening, routine hematology follow-up, and essential preventive care such as vaccination and prophylactic antibiotics.Even in the United States, where approximately 100,000 individuals are affected and newborn screening is widespread, gaps in guideline-concordant care persist.

A meaningful share of patients do not consistently receive disease-modifying therapies, particularly in socioeconomically disadvantaged communities. These gaps contribute to recurrent vaso-occlusive crises, high emergency utilization, and avoidable mortality, while also leaving many patients outside specialist pathways where advanced therapies would be considered.

While improvements in screening and adherence could unlock incremental demand, public health investment in many low- and middle-income countries remains insufficient to scale universal screening and chronic care programs over the next decade.

For industry, low diagnosis and adherence rates shrink the effective eligible population, limit real-world evidence generation, and weaken the case for field force expansion in emerging markets, justifying a conservative 1.0 percentage-point downward adjustment to long-term global CAGR forecasts until care pathways materially strengthen.

Opportunity

Expanded newborn and carrier screening bundles in high burden regions.
Despite clear evidence that early diagnosis and preventive care improve survival and reduce under five mortality in SCD endemic regions, systematic newborn screening and carrier testing remain limited in many high prevalence geographies, particularly sub Saharan Africa, India, and parts of the Middle East.

The opportunity is to bundle low cost, high throughput SCD newborn screening assays and carrier tests into population health programs purchased by Ministries of Health or large insurers, creating recurring diagnostics revenue and a predictable flow of patients into structured care pathways.

If global annual SCD births exceed 300,000 and approach 400,000 by mid century, and expanded screening raises early diagnosis rates from roughly 20 to 30% today to 60 to 70 percent by 2035, the number of patients entering documented care would double or triple.

Each diagnosed patient represents 10 to 20 years of incremental, better adhered chronic therapy use and more orderly progression into advanced therapies.At screening prices of a few dollars per test, annual diagnostics revenue could reach the low hundreds of millions of dollars, while the larger upside lies in unlocking several billions in lifetime therapeutic revenue otherwise lost to late diagnosis and early mortality.

This upside is not embedded in baseline forecasts and would require coordinated policy advocacy, public private partnerships, and integrated contracting, yielding an estimated 1.0% point CAGR uplift as diagnosed cohorts expand faster than demographics alone.

Regional Analysis

Regional Analysis of Sickle Cell Disease Treatment Market.

In 2025, North America led the Sickle Cell Disease Treatment Market, accounting for over 42.1% of the global market share with revenue of approximately US$ 1.5 Billion. The region’s dominance is primarily driven by the high prevalence of sickle cell disease, advanced healthcare infrastructure, strong adoption of innovative therapies, and significant investment in research and development.

The United States represents the major contributor due to increased access to disease-modifying therapies, advanced diagnostic capabilities, and the presence of leading biotechnology and pharmaceutical companies focused on gene therapies and targeted treatments.

Europe holds a significant position in the market, supported by increasing awareness of inherited blood disorders, improved patient management programs, and favorable healthcare policies promoting access to advanced treatments. Countries such as the United Kingdom, Germany, and France are investing in clinical research and personalized medicine approaches for sickle cell disease management.

The Asia-Pacific region is expected to witness notable growth due to rising disease awareness, improving healthcare systems, and expanding availability of specialized treatment options. Increasing government initiatives for rare disease management and growing investments in healthcare infrastructure are supporting market expansion across emerging economies.

Latin America and the Middle East & Africa regions are gradually developing due to improving diagnostic facilities and increasing focus on rare blood disorder treatments. However, limited healthcare access, lower awareness levels, and treatment affordability challenges continue to restrict faster adoption in these regions. Overall, advancements in gene therapy, novel drug development, and broader healthcare accessibility are expected to drive global market growth.

Key Regions and Countries

North America

• The US
• Canada

Europe

• Germany
• France
• The U.K.
• Italy
• Spain
• Russia & CIS
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

Latin America

• Brazil
• Mexico
• Rest of Latin America

Key Player Analysis

The Sickle Cell Disease Treatment Market demonstrates a moderately consolidated competitive structure, with leading pharmaceutical and biotechnology companies driving innovation through advanced therapies, targeted drug development, and gene-editing approaches. Competition is shaped by the growing focus on disease-modifying treatments, curative therapeutic strategies, and improved patient outcomes.

Companies are investing significantly in research and development (R&D) to advance novel molecules, gene therapies, and precision medicine platforms. The market landscape includes established pharmaceutical players as well as biotechnology firms specializing in next-generation treatment technologies.

Agios Pharmaceuticals focuses on developing innovative therapies targeting underlying disease mechanisms, while Bristol-Myers Squibb emphasizes expanding its hematology portfolio through research-driven product development.

CRISPR Therapeutics and Editas Medicine are advancing gene-editing platforms aimed at potential curative solutions for sickle cell disease. Emmaus Life Sciences Inc. and Medunic USA Inc. focus on therapeutic options addressing disease management and patient needs.

Novartis AG and Vifor Pharma strengthen market competition through specialized healthcare solutions and global commercialization capabilities. bluebird bio Inc. and Vertex Pharmaceutical are advancing gene therapy and combination treatment approaches.

Competitive strategies across the market emphasize R&D investments, strategic partnerships, workflow integration in healthcare delivery, and ecosystem-based approaches connecting diagnostics, treatment access, and long-term disease management.

Top Key Players

• Agios Pharmaceuticals
• Bristol-Myers Squibb
• CRISPR Therapeutics
• Editas Medicine
• Emmaus Life Sciences Inc.
• Medunic USA Inc.
• Novartis AG
• Vifor Pharma
• bluebird bio Inc.
• Vertex Pharmaceutical

Recent Developments

• In June 2026, Agios entered an exclusive global licensing agreement with Oscotec to develop and commercialize cevidoplenib, a next-generation SYK inhibitor. The agreement included a $25 million upfront payment with additional development, regulatory, and commercial milestone payments. Although focused beyond SCD, the deal reflects Agios’ strategy of expanding its rare hematology pipeline and reducing dependence on a single therapeutic platform.
• In July 2026, Vertex Pharmaceuticals announced expanded FDA approval for CASGEVY (exagamglogene autotemcel), a CRISPR/Cas9 gene-editing therapy developed through the Vertex–CRISPR collaboration. The expanded indication allows treatment of patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises. This milestone significantly expanded access to gene-editing therapy and strengthened the position of CRISPR-based treatments in the SCD market.

Report Scope